Annual Drug Patent Expirations for BANZEL
Banzel is a drug marketed by Eisai Inc and is included in two NDAs. It is available from one supplier. There is one patent protecting this drug and two Paragraph IV challenges.
Drug patent litigation for BANZEL.
The generic ingredient in BANZEL is rufinamide. One supplier is listed for this compound. Additional details are available on the rufinamide profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
